Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE.

Rheumatology (Oxford) · 2022 · PMC9071547 · PMID 34528079

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

markedly significantno p-value reported

A markedly significant difference between secukinumab and placebo was observed as early as 1 week after treatment initiation.

also in 476 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.